Trials / Completed
CompletedNCT05930925
A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults
AN INTERVENTIONAL, PHASE 1, OPEN-LABEL, 2-ARM PARALLEL STUDY TO INVESTIGATE THE ABSORPTION, METABOLISM, AND EXCRETION OF [14C]ARV-471 IN HEALTHY ADULT PARTICIPANTS
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to understand how the study medicine ARV-471 is processed in the body of healthy males and females who do not have the potential to have children. This study is seeking for participants who: * are healthy males and females who do not have the potential to have children. * are 18 years of age or older. * weigh more than 110 pounds.
Detailed description
About 6 participants each will receive a single dose of either type of ARV-471. They are taken as liquid suspensions by mouth. Participants will stay in the study site for about 13 days and 12 nights.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [phenyl-14C]ARV-471 | Participants will receive a single dose of \[phenyl-14C\]ARV-471 by mouth |
| DRUG | [oxoisoindolin-14C]ARV-471 | Participants will receive a single dose of \[oxoisoindolin-14C\]ARV-471 by mouth |
Timeline
- Start date
- 2023-06-12
- Primary completion
- 2023-07-27
- Completion
- 2023-08-14
- First posted
- 2023-07-05
- Last updated
- 2023-09-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05930925. Inclusion in this directory is not an endorsement.